BRIEF—Diurnal to launch Alkindi in Europe after gaining pediatric use approval

AIM-listed Diurnal has been granted a paediatric use marketing authorisation (PUMA) in Europe for Alkindi (hydrocortisone) as replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents.

The therapy is specifically designed to provide the first regulated, consistent preparation of hydrocortisone to ensure efficacy and safety and ease of use for children suffering from AI.

The firm says it will commercialise the product itself, with the first country launch anticipated in the the next few months.